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FRAUD AND THE MEDICAID DRUG REBATE PROGRAM
Kyle Mitchell
Introduction
Among the numerous drug manufacturers that have been recently charged with violating
the Medicaid Drug Rebate Program, Mylan Pharmaceuticals and their product, EpiPen, has been
one of the most highly publicized. The issue arises when considering the distinction between a
drug product being classified as an innovator or a non-innovator drug for rebate purposes. While
the distinction at first may seem to be a simple matter of nomenclature, the amount of correlated
rebate payments is substantial. As of January 2016, The Center for Medicare and Medicaid
Services (“CMS”) has enacted its Covered Outpatient Drugs final rule with comments.1 This
final rule was aimed to clarify the discrepancy between the classification of innovator and noninnovator drugs for manufacturers involved in the Medicaid Drug Rebate Program. While this
rule has helped to distinguish the two classifications, it has left a void where companies such as
Mylan have products that can fall into either category. Manufacturers have developed products
that contain aspects of both innovator and non-innovator status and will be further known as
drug-device combination products (“DDCP”)2. These products have been mislabeled in the past,
and will continue to be mislabeled until a proper rule is implemented to clarify the confusion.3
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Medicaid Drug Rebate Program, MEDICAID.GOV: KEEPING AMERICA HEALTHY,
https://www.medicaid.gov/medicaid/prescription-drugs/covered-outpatient-drug-policy/index.html, (last visited
Mar. 25, 2017).
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About Combination Products, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: U.S. FOOD & DRUG
ADMINISTRATION, https://www.fda.gov/CombinationProducts/AboutCombinationProducts/default.htm (last updated
Sept. 08, 2016).
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James Matthews et al., The EpiPen Controversy Signals Intensifying Scrutiny of Drug Classification Under
Medicaid Rebate Program, HEALTHCARE LAW TODAY, (Sept. 07, 2016),
https://www.healthcarelawtoday.com/2016/09/07/the-epipen-controversy-signals-intensifying-scrutiny-of-drugclassification-under-medicaid-rebate-program/, (last visited Mar. 22, 2017).
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The purpose of this paper is to introduce a proposed legislative solution to be
implemented by CMS to help resolve the aforementioned issue. The first section will define what
the Medicaid Drug Rebate Program is, the process a manufacturer must go through to enroll, and
what an innovator and non-innovator classification entail. The second section goes through
varying examples of drug manufacturers who have misclassified their products for rebate
purposes and have consequently paid significant financial penalties. The third section discusses
CMS’s final rule with comments and its’ narrow exception. The fourth section contains a
proposed legislative solution to the categorization issue caused by DDCPs. The final section
discusses how manufacturer misclassification may be actionable under the False Claims Act.
I.

Medicaid Drug Rebate Program
The Medicaid Drug Rebate Program (“MDRP”), was established by Congress in 1990 as

part of the Omnibus Budget Reconciliation Act and authorized by Section 1927 of the Social
Security Act.4 The purpose of the enactment was to control the cost of prescription drugs covered
under Medicaid by offsetting federal and state costs.5 The program encompasses CMS, State
Medicaid Agencies, and the drug manufacturers in participation.6 There are approximately 600
drug manufacturers in participation, and currently all fifty states cover prescription drugs under
the program.7
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Stefanie Berman, A Legislative History of the Medicaid Drug Rebate Law: The Drug Industry and the Crusade of
Senator David Pryor, HARVARD UNIVERSITY DASH, (Mar. 19, 2004)
https://dash.harvard.edu/bitstream/handle/1/8965555/Berman.pdf?sequence=1.
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Medicaid Drug Rebate Program, MEDICAID.GOV: KEEPING AMERICA HEALTHY,
https://www.medicaid.gov/medicaid/prescription-drugs/medicaid-drug-rebate-program/index.html,
(last updated June 16, 2016).
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a. Enrollment Process
The first step to admission is a requirement that the drug manufacturer enters into a
national rebate agreement with the Secretary of the Department of Health and Human Services
(“HHS”) in exchange for state Medicaid coverage.8 This has the potential to include a large
proportion of the manufacturer’s drugs. Second, when the manufacturer markets a new covered
drug, it must provide the drug’s product and pricing data to CMS via the Drug Data Reporting
(“DDR”).9 Third, manufacturers must pay a certain rebate amount for which payment was made
under the state plan.10 The rebates are to be paid on a quarterly basis to the states, which then
share with the federal government, to help offset the price.11 Finally, in addition to signing a
national rebate agreement, drug manufacturers are required to enter into two other federal
program agreements in order to have their drugs covered.12 The two agreements include a pricing
agreement for the Section 340B Drug Pricing Program13 and a Master agreement with the
Secretary of Veteran Affairs for the Federal Supply Schedule.14
b. Innovator v. Non-Innovator
The drugs are then classified into two categories: innovator and non-innovator. A
statutory formula is used to determine the amount rebate due for each unit of the drug.15
Innovator drugs either owe 23.1% of the Average Manufacturer Price (“AMP”) per unit or the
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SERVICES ADMINISTERED, https://www.hrsa.gov/opa/, (last reviewed Mar. 2017).
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Medicaid Drug Rebate Program, MEDICAID.GOV: KEEPING AMERICA HEALTHY,
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(last updated June 16, 2016).
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difference between the AMP and the best price per unit (this is adjusted by the Consumer Price
Index-Urban (“CPI-U”) based on launch date and current quarter AMP).16 The cap on the total
rebate amount for each innovator drug is at 100% of the AMP.17 Non-innovator drugs owe 13%
of the AMP per unit.18 This 10% distinction can be crucial between having a product classified
as an innovator or non-innovator. In the case of large pharmaceuticals companies, this has the
potential to cost the states and their tax payers millions of dollars.19 Following the passage of the
Affordable Care Act, generic drugs have been exempted from the additional inflationary rebate
applied to brand drugs for which AMP increases faster than the rate of inflation.20
II.

MDRP and Fraud
Based on the large discrepancy in rebate amounts, numerous pharmaceutical companies

have attempted to classify their products as non-innovators. Whether these acts are intentional or
not, companies such as Mylan Pharmaceuticals, Dava Pharmaceuticals, KV Pharmaceuticals,
UDL Laboratories, Inc., AstraZeneca Pharmaceuticals LP, and Ortho McNeil Pharmaceutical,
Inc., each has faced adverse judgments for misclassification. When determining whether a drug
should be classified as an innovator or non-innovator, there are two key factors to evaluate. The
first factor is whether the active pharmaceutical ingredient (“API”) is an innovator or noninnovator medication. The FDA defines APIs as follows:
[A]ny substance or mixture of substances intended to be used in the
manufacture of a drug product and that, when used in the production
16
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Ed Silverman, Feds slam Mylan for misclassifying EpiPen, with ‘financial consequences’ to Medicaid, STAT,
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of a drug, becomes an active ingredient in the drug product. Such
substances are intended to furnish pharmacological activity or other
direct effect in the diagnosis, cure, mitigation, treatment or
prevention of disease or to affect the structure and function of the
body.21
An example of a generic API can be demonstrated as follows: if you had a headache, you would
take Tylenol or Advil. The generic active ingredient found in both is acetaminophen.
a. New Drug Application v. Abbreviated New Drug Application
The second factor is whether the drug is marketed under an abbreviated new drug
application (“ANDA”) or a new drug application (“NDA”). A NDA is a submission by a drug
manufacturer, to the FDA, when the sponsor of a new drug believes enough evidence on the
drug’s safety and effectiveness has been obtained to meet FDA’s requirements for marketing
approval.22 The application must contain data from specific technical viewpoints for review.
These include: chemistry, pharmacology, medical, biopharmaceutics, and statistics.23 If the NDA
is granted approval, the product is permitted marketing rights in the United States.24
In contrast, an ANDA is submitted to the FDA’s Center for Drug Evaluation and
Research. The ANDA must be accompanied with data that provides for review and ultimate
approval of a generic drug product.25 ANDAs are abbreviated because they are generally not
required to include preclinical (animal) and clinical (human) testing data to demonstrate safety
and effectiveness.26 Instead, a generic applicant must establish that its’ product is bioequivalent

21

Edward Lamb, What Are Active Pharmaceutical Ingredients, or APIs?, THE BALANCE,
https://www.thebalance.com/what-are-active-pharmaceutical-ingredients-or-apis-2663827, (last updated July 28,
2016).
22
Types of Applications, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: U.S. FOOD & DRUG
ADMINISTRATION,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplicati
ons (last updated Oct. 23, 2014).
23
Id.
24
Id.
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Id.
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(i.e., performs in the same manner as the innovator drug).27 Once approved, the generic product
can be marketed as a safe, effective, and lower costing alternative to a brand name drug.28 While
it may seem this distinction makes the classifications between NDAs and ANDAs rather black
and white, a shade of grey is added when dealing with DDCPs. These products include both a
brand name administering device and a generic drug. To elaborate on this point, The New York
Times reported that many old medications are being delivered in new packages. These
medications include asthma inhalers, insulin injectors, and emergency rescue drugs like
GlucaGen and Narcan, both utilize generic APIs administered by new intramuscular autoinjectors.29
b. Illustrations of Past Misclassifications
Mylan Pharmaceuticals has come under fire in recent media for the significant price
increase of its EpiPen product. The price has dramatically increased 548% over the past decade
to $608 for a two-pack device.30 This was further exacerbated by the fact that Mylan had been
misclassifying its product as a non-innovator drug, relying on a 1997 letter from CMS. This
letter was written to Dey Laboratories, which Mylan purchased in 2007, noting that it was
“fitting and proper” to classify EpiPen as a “non-innovator” or generic drug product.31 The letter
reads,

27
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Types of Applications, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES: U.S. FOOD & DRUG
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ons (last updated Oct. 23, 2014).
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James Matthews et al., The EpiPen Controversy Signals Intensifying Scrutiny of Drug Classification Under
Medicaid Rebate Program, HEALTHCARE LAW TODAY, (Sept. 07, 2016),
https://www.healthcarelawtoday.com/2016/09/07/the-epipen-controversy-signals-intensifying-scrutiny-of-drugclassification-under-medicaid-rebate-program/.
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Ed Silverman, Mylan overcharged Medicaid for EpiPen for years, despite warnings, STAT, (Oct. 05, 2016),
https://www.statnews.com/pharmalot/2016/10/05/mylan-overcharged-medicaid-epipen/.
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Ed Silverman, Mylan to pay $465 million to settle claims of shortchanging Medicaid, STAT, (Oct. 07, 2016),
https://www.statnews.com/pharmalot/2016/10/07/myland-465-million-settlement-epiped-medicaid/.
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[I]n order to determine the Drug Category . . . to use when reporting
[EpiPen] to the MDRP. Because these products are included in a
package with a new delivery system, they are listed by the FDA
under a NDA (New Drug Application), HCFA stated; however,
“[t]he products themselves . . . are listed under an ANDA
(Abbreviated New Drug Application) because they are very old
products and made by many generic drug companies. HCFA
concluded, even though the current NDCs of these products . . . are
listed under an NDA, it is entirely fitting and proper . . . to report
them to the Drug Rebate Program with a Drug Category of ‘N’
(Non-innovator, Multiple Source) and be subject to the lowest rebate
amount of 11% of quarterly AMP.32
From 2011 to 2015, Medicaid spent $797 million on EpiPen after rebates.33 Acting CMS
administrator Andy Slavitt noted, Mylan should have been paying 23.1% instead of 13%, but
failed to do so because the company improperly classified EpiPen as a generic, despite being told
its classification was incorrect.34 This is a taxpayer issue because states and the federal
government use the rebates from drug manufacturers to offset the cost of covered medicines.
Although the entire amount of EpiPen sales does not go directly to Medicaid, Evercore ISI
analyst, Umer Raffat, has estimated that about 20% of sales have.35 In October 2016, Mylan
agreed to a $465 million settlement with the U.S. Department of Justice.36 Although it was
originally believed EpiPen would be relabeled as a brand-name drug by April 2017, recent
reports state Mylan will be fighting this change.
The second example of misclassification involves a Delaware-based corporation, Dava
Pharmaceuticals. Brought under the False Claims Act (“FCA”), Dava was charged with
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James Matthews et al., The EpiPen Controversy Signals Intensifying Scrutiny of Drug Classification Under
Medicaid Rebate Program, HEALTHCARE LAW TODAY, (Sept. 07, 2016),
https://www.healthcarelawtoday.com/2016/09/07/the-epipen-controversy-signals-intensifying-scrutiny-of-drugclassification-under-medicaid-rebate-program/.
33
Ed Silverman, Mylan overcharged Medicaid for EpiPen for years, despite warnings, STAT, (Oct. 05, 2016),
https://www.statnews.com/pharmalot/2016/10/05/mylan-overcharged-medicaid-epipen/.
34
Id.
35
Id.
36
Ed Silverman, Mylan to pay $465 million to settle claims of shortchanging Medicaid, STAT, (Oct. 07, 2016),
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underpaying their rebate obligations through the MDRP between October 2005 and September
2009.37 The participating states and the federal government found that Dava had misclassified
three of their drugs as non-innovator drugs for Medicaid rebate purposes.38 Dava paid a total of
$11 million between state and federal damages to compensate Medicaid and various federal
healthcare programs for its conduct.39
The third example involves KV Pharmaceutical’s failure to advise CMS that two of its’
unapproved products did not qualify for coverage under federal and state health care programs. 40
According to the settlement, Ethex (subsidiary of KV) submitted false quarterly reports to the
government relating to two of its’ drugs.41 Although the FDA deemed the drugs “less than
effective” and ineligible for reimbursement by the government under Medicaid, Ethex actively
promoted them as effective for rebate purposes.42 KV was required to pay a total of $17 million
to Medicaid and various federal healthcare programs to compensate for its conduct.43
The final example, occurring in 2009, involved four pharmaceutical companies, Mylan
Pharmaceuticals, Inc., UDL Laboratories, Inc., AstraZeneca Pharmaceuticals LP, and Ortho
McNeil Pharmaceutical, Inc. Each settled as part of a Medicaid underpaid rebate fraud case.44

37

A.G. Schneiderman Announces $28 Million in Settlements With Two Pharmaceutical Companies for Violating
Medicaid Regulations, ATTORNEY GENERAL ERIC T. SCHNEIDERMan, (Mar. 01, 2012)
http://www.ag.ny.gov/press-release/ag-schneiderman-announces-28-million-settlements-two-pharmaceuticalcompanies.
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A.G. Schneiderman Announces $28 Million in Settlements With Two Pharmaceutical Companies for Violating
Medicaid Regulations, ATTORNEY GENERAL ERIC T. SCHNEIDERMan, (Mar. 01, 2012)
http://www.ag.ny.gov/press-release/ag-schneiderman-announces-28-million-settlements-two-pharmaceuticalcompanies.
44
NC Wins $3.5 Million From 4 Drug Makers, Says AG Cooper: Pharmaceutical companies underpaid rebates to
Medicaid, NORTH CAROLINA DEPARTMENT OF JUSTICE ATTORNEY GENERAL ROY COOPER, (Oct. 20, 2009)
http://www.ncdoj.gov/News-and-Alerts/News-Releases-and-Advisories/Press-Releases/NC-wins-$3-5-millionfrom-4-drug-makers,-says-AG-C.aspx.
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The four companies were required to pay a total of $124 million nationally including $3.5
million to North Carolina.45
These examples serve as demonstrations that the EpiPen incident was not an outlier, and
that this type of fraud needs to be properly addressed as it affects the government’s budget and
the U.S. taxpayers.
III.

CMS’s Final Rule and the Narrow Exception
On January 21, 2016, CMS released its Covered Outpatient Drugs final rule to help

combat the misclassification issue.46 The primary objective was to address key areas and changes
of the MDRP under the Affordable Care Act. The rule assists states and the federal government
in managing drug costs, establishes the long-term framework for implementation of the MDRP,
and creates a fairer reimbursement system for Medicaid programs and pharmacies.47 It attempts
to manage drug costs by establishing a definition of AMP for inhalation, infusion, instilled,
implanted, or injectable drugs, so states can collect rebates on more expensive infused and
injected drugs, which are an increasing expense to the Medicaid program.48 The deadline for
compliance with this rule is March 31, 2017.49 In efforts to expand the program, the scope of the
word “state” will now incorporate U.S. territories by April 1, 2020.50 Under 81 Fed. Reg. 5170,
5193, “[a]ll drugs marketed under an NDA, other than an ANDA, regardless of when they were

45

Id.
Covered Outpatient Drugs Policy, MEDICAID.GOV,
https://www.medicaid.gov/medicaid/prescription-drugs/covered-outpatient-drug-policy/index.html, (last accessed
Mar. 25, 2017).
47
Ned Milenkovich, CMS releases final rule for covered outpatient drug, MODERNMEDICINE NETWORKS: DRUG
TOPICS, (Apr. 10, 2016), http://drugtopics.modernmedicine.com/drug-topics/news/cms-releases-final-rule-coveredoutpatient-drugs?page=0,0,.
48
Id.
49
Chris Cobourn, CMS Issues Guidance on Drug Category Narrow Exception, HURON,
https://www.huronconsultinggroup.com/resources/life-sciences/drug-category-narrow-exception-guidance-fromcms, (last accessed Mar. 13, 2017).
50
Covered Outpatient Drugs Policy, MEDICAID.GOV: KEEPING AMERICA HEALTHY,
https://www.medicaid.gov/medicaid/prescription-drugs/covered-outpatient-drug-policy/index.html, (last accessed
Feb. 25, 2017).
46
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approved, should be categorized as single source or innovator multiple source drugs, unless CMS
determines that a narrow exception applies as discussed pursuant to this final rule.”51 Further
stating “[t]here may be very limited circumstances where, for the purposes of the Medicaid Drug
Rebate (MDR) program, certain drugs might be more appropriately treated as if they
were approved under an ANDA and classified as a non-innovator multiple source drug.”52
The narrow exception deals with certain drugs approved under a paper NDA prior to the
enactment of the Hatch-Waxman Amendments of 1984 or under certain types of literature-based
505(b)(2) NDA approvals after the Hatch-Waxman Amendments of 1984.53 The Hatch-Waxman
Amendments provided some protection for drug innovators while facilitating and providing
incentives for companies to file ANDAs.54 This Act came to be following the drug regulations of
the early 1960’s. After 1962, the FDA added the requirement that drugs must be approved for
effectiveness and not just safety.55 This additional requirement lead generic drug companies to
stop competing as they did not want to allocate the additional financial resources to conduct
clinical trials.56 After the passing of the Hatch-Waxman Act, the regulations to get to market
were lessened, while still ensuring their products were safe and effective.57 The regulatory
pathways to get ANDA approval around that time were uncertain. With this in mind, it would be

51

James Matthews et al., The EpiPen Controversy Signals Intensifying Scrutiny of Drug Classification Under
Medicaid Rebate Program, HEALTHCARE LAW TODAY, (Sept. 07, 2016),
https://www.healthcarelawtoday.com/2016/09/07/the-epipen-controversy-signals-intensifying-scrutiny-of-drugclassification-under-medicaid-rebate-program/.
52
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Chris Cobourn, CMS Issues Guidance on Drug Category Narrow Exception, HURON,
https://www.huronconsultinggroup.com/resources/life-sciences/drug-category-narrow-exception-guidance-fromcms, (last accessed Mar. 13, 2017).
54
Amanda Baltazar, The Hatch-Waxman Act – How it Changed the Pharm Industry: Changing the Playing Field for
Branded and Generic Drugs, THE BALANCE, https://www.thebalance.com/the-hatch-waxman-act-how-it-changedthe-pharma-industry-2663817, (last updated May 15, 2016).
55
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more appropriate to treat certain NDAs approved around that time as ANDAs and classify them
as non-innovator drugs.
Manufacturers will have four quarters, after the April 1, 2017 effective date, to submit
appropriate materials to CMS demonstrating why the narrow exception should apply.58 Included
in submission, a manufacturer may include information such as a copy of the FDA approval
letter for an NDA or any indication that the drug never received patent protection/market
exclusivity.59 These few examples do not constitute an exhaustive list of materials a
manufacturer may include. Following the application for a narrow exception, CMS will review
these materials and make one of two decisions. They will either confirm in writing that this
narrow exception does apply to the drug at issue and permit reclassification as a non-innovator
multiple source drug; or state that the exception does not apply, and the manufacturer must
continue to report the drug as either a single source or innovator multiple source drug.60
Manufacturers may not rely on previous written communications from CMS to justify
classification of a drug marketed under an NDA as a non-innovator drug.61
IV.

Proposed Solution
With CMS’s final rule set for implementation this calendar year, the issue of classifying

certain DDCPs is still seeking a solution. The proposed legislation will be based on the
foundation of CMS’s final rule and will be first published six-months after the March 2017
deadline for narrow exception applications. After the final rule takes effect, any drug that is
approved under a NDA will be considered an innovator drug and will be subject to the 23.1%

58

Chris Cobourn, CMS Issues Guidance on Drug Category Narrow Exception, HURON,
https://www.huronconsultinggroup.com/resources/life-sciences/drug-category-narrow-exception-guidance-fromcms, (last accessed Mar. 12, 2017).
59
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60
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rebate amount. Any application that is approved under an ANDA will be considered a noninnovator drug and held to the 13% rebate amount. If a classification does not seem appropriate,
the manufacturer is capable of appealing for a narrow exception, but it must be submitted by the
March 31, 2017 deadline.62 This proposed legislation will seek to answer what DDCPs who are
still questioning their classification status should do after the March 2017 deadline. Much like
Mylan’s EpiPen, a legitimate argument will exist that while the administering device is patented
and qualified under a NDA, the administered drug may still be a generic drug under an ANDA.
The proposed legislation will provide two options regarding the classification of these
DDCPs: (1) the creation of a definitive bright line rule in regards to these products, or; (2) the
creation of a new intermediate classification under the MDRP.
a. Option One: Bright Line Rule and Patent Exclusivity Waivers
The first option creates a bright line rule to help resolve issues with classification for
manufacturers who have failed to fall under CMS’s narrow exception. There will be new
guidelines to follow if a manufacturer wants its’ drug to possess the potential to be a noninnovator drug and pay the lesser rebate. The first guideline involves patent exclusivity waivers.
When a drug is approved under a NDA it is granted New Drug Product Exclusivity under the
Federal Food, Drug, and Cosmetic Act under section 505(c)(3)(E) and 505(j)(5)(f).63 In 1984,
Title 1 of the Hatch-Waxman Amendments was amended to provide for New Drug Product
Exclusivity in an attempt to encourage research and development.64 Exclusivity provides the
applicant of an approved NDA certain protection against the competition in the market. This

62

Id.
Small Business Assistance: Frequently Asked Questions for New Drug Product Exclusivity, U.S. DEPARTMENT OF
HEALTH AND HUMAN SERVICES: U.S. FOOD & DRUG ADMINISTRATION,
http://www.fda.gov/Drugs/DevelopmentApprovalProcess/SmallBusinessAssistance/ucm069962.htm, (last accessed
Feb. 18, 2017).
64
Id.
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protection precludes approval of certain 505(b)(2) applications or certain ANDAs for a period of
time.65 Once approved, the NDA is granted a five-year period of exclusivity if the product
contained chemical entities never previously approved, either alone or in combination.66 During
this five-year period, no 505(b)(2) ANDA applications may be submitted unless an exclusion
applies. Examples of these exclusions include: orphan drug exclusivity, pediatric exclusivity, and
a four-year submission exclusion is allowed if the application contains a certification of patent
invalidity or non-infringement.67 When a product receives any length of exclusivity it is
registered in the Orange Book & Supplements where other manufacturers can view what
products are currently under patent.
The exclusivity waiver will not be retroactive in nature. Meaning any current exclusivity
rights a manufacturer possesses will be honored. This legislation targets NDA applicants. They
will be provided two options following a submission. The first option states, if the applicant
plans to use their maximum exclusivity rights and become enrolled in the MDRP, they will be
approved for innovator status and the corresponding 23.1% rebate amount as described in the
current final rule.
The second option, assuming their patent will no longer be protected after the time limit,
will allow the manufacturer to either partially or fully waive their exclusivity rights upon
acceptance of their application and, if enrolled in the MDRP, be classified as a non-innovator.
Waiving valuable years of patent protection may initially seem to be a detriment, as
manufacturers will not possess the allotted time against competition. This time is crucial in an
attempt to collect the funds they expelled for research and development. The incentive of the

65

Id.
Id.
67
Id.
66
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waiver will be that the federal government will reimburse the manufacturer a percentage of their
research and development costs depending on how many years of patent protection they waive.
For example, if a manufacturer is granted the full five-years of exclusivity after its NDA is
approved, and it chooses to waive the entire five-years, the government will reimburse the entire
amount of research and development that was spent creating the drug. The scale of
reimbursement will be fixed on 20% per one year waived of exclusivity rights. To illustrate, if a
manufacturer waives one year of exclusivity, the government will reimburse 20% of the total
research and development costs. If they waive two years, 40% of reimbursement, three years,
60% of reimbursement, four years, 80% of reimbursement. This would provide the manufacturer
with the decision of whether to take the risk and keep the full five-year protection and receive no
guaranteed government reimbursement, or to take the guaranteed reimbursement, but fall victim
to the invisible hand of the market and lose the protection against competition. This will require
the manufacturer to conduct a risk-benefit analysis of any financial factors involved and to
decide whether receiving the reimbursement along with the lower rebate percentage will fit their
business plan.
Opponents of the waiver provision may be skeptical that without exclusivity rights,
pharmaceutical companies may decide investing in new drugs is not a prudent business decision.
The reimbursement payments should provide an adequate incentive for drug manufacturers to
continue to strive for innovative new cures to ailments in the present and in the future. This will
also help solidify whether a drug is an innovator or non-innovator to avoid potential fraudulent
activity regarding rebates.

14

b. Option Two: Intermediate Classification
The second solution is to create an intermediate classification for DDCPs. By creating
this new category, all parties involved will need to provide flexibility that in return will help
eliminate any excess spending. This may be in the form of government funds saved, or the
manufacturers avoiding potential lawsuits down the road. Instead of paying the innovator rebate
price of 23.1% of AMP, or the non-innovator price of 13% of AMP, a product that has the
capacity to fit under either will pay 18% in rebates. This intermediate classification would be
sustained until the patent exclusivity of a NDA approval would expire, subsequently allowing the
company to reclassify as a generic or reapply for another NDA.
An alternative way for a manufacturer to place their product in the intermediate category
would be measuring the products effects in degrees of medical necessity. For the purpose of this
paper, the federal standard for medical necessity will an adoption of California’s definition of the
term. This is because the current federal standard is not defined under the Medicaid Act. The
standard’s definition of medical necessity will be satisfied if a treatment is reasonable and
necessary to prevent significant illness or disability, relieve severe pain, or save someone’s life. 68
Following this definition, if a NDA approved product fails to fall under the narrow exception, a
manufacturer will be able to file a separate appeal for the intermediate classification by showing
that their product is not used in medically necessary treatments. The rationale behind this
decision is that when a NDA is approved, there is market exclusivity on the product. By
decreasing the amount of rebate percentage that the manufacturer owes, they may be less
incentivized to raise the price of their products. By owing less in rebates to the government and
states, replenishing their research and development funds will become more attainable without
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raising the price of their drug. Gaining access to the intermediate classification will provide a
definitive rebate percentage to help eliminate potential future fraud.
Implementation of this legislation will be handled similarly to other notices published by
CMS. An initial notice will be published containing all of the provisions mentioned previously
and a proposition to assist in the definition of certain DDCPs that have the potential for
involvement in fraudulent classification. Upon the publication date, practitioners, consumers, and
manufacturers will be allowed to provide comments on the proposed changes within a six-month
period. These comments, along with any alternatives that are presented, will be taken into
consideration. Following a three-month period of idea consolidation, a second final notice will
be published. This notice will follow a more structured format and will include any ideas and
alternative options provided from the comments from the first published notice that CMS has
deemed to be both acceptable and practical. This second notice will be open to any further
comments from the aforementioned parties for a span of six-months. Upon closure of the second
notice, a finalized publication will be issued. There will be a one-year compliance grace period
where manufacturers will then be on notice of the new changes to classifications of drug
products that are enrolled in the MDRP. After the new rule is implemented, any new applications
for NDAs will be facilitated following the new guidelines.
V.

False Claims Act Liability
The False Claims Act, 31 U.S.C. § 3729(a) (“FCA”) provides a cause of action against

“any person who . . . knowingly presents, or causes to be presented, a false or fraudulent claim
for payment or approval, or . . . knowingly makes, uses or causes to be made or used, a false
record or statement material to a false or fraudulent claim.”69 The Act’s scienter requirement
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defines “knowing” and “knowingly” to mean that a person has “actual knowledge of the
information,” “acts in deliberate ignorance of the truth or falsity of the information,” or “acts in
reckless disregard of the truth or falsity of the information.”70 The Act defines “material” to
mean “having a natural tendency to influence, or be capable of influencing, the payment or
receipt of money or property.”71 Persons who are in violation of the Act are liable for treble
damages (three times the actual damages which the government sustains).72 Defendants found
liable are further required pay a mandatory penalty (between $5,00 and $10,000) for each false
claim.73
Under the FCA, private individuals, known as relators, can bring qui tam suits against the
pharmaceutical or health care company.74 These actions were created to encourage private
individuals to report wrongs against the government by providing a financial incentive.75 Once
the whistleblower has initiated the qui tam action, the government has two main options. First,
the government may choose to intervene and take over the lawsuit.76 This will result in the
relator receiving 15-25% of the recovered funds. Second, if the government chooses not to
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intervene, the relator can continue the lawsuit independently and collect between 25-30% of the
recoveries.77
Mylan Pharmaceutical relies on a 1997 letter from CMS when determining its’ product
was able to be classified as a non-innovator drug instead of an innovator.78 Under the language
of the FCA, manufacturers should be held liable for misclassifying their products under the
MDRP, because in doing so, they are knowingly misrepresenting the amount of rebate they owe
to the government. The 2016 Supreme Court case, United Health Services v. United States ex.
rel. Escobar, 136 S. Ct. 1989 demonstrates how manufacturers with prior CMS approval to
classify their products as non-innovator drugs may possess the ability to prove they lacked the
scienter requirement to qualify for a FCA violation. The Escobar court held that a manufacturer
can be held liable under the FCA for misrepresentations if it makes specific representations about
the goods or services provided, but fails to disclose noncompliance with material statutory,
regulatory, or contractual requirements.79 This means that a manufacturer enrolled in the MDRP
may be held liable under the FCA for failing to disclose their product’s misclassification, even if
they accurately represent their product under the program. In the case of Mylan, they possessed
previous contact with CMS in the 1997 letter. This would make it difficult for CMS to show the
misclassification was material, since they previously had the opportunity to declare EpiPen an
innovator drug as chose not to. Therefore, while this may allow Mylan to avoid the scienter
requirement under the FCA, other manufacturers may not possess the prior CMS
acknowledgment to avoid FCA violations.
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Pursuing pharmaceutical manufacturers knowing misrepresentations under FCA liability,
will provide the necessary deterrent effect to minimize misclassification fraud. The FCA
provides for three main sources of deterrence to ensure manufacturer’s of DDCPs do not
misclassify their products, and instead present an inquiry to CMS before applying.
First, if an FCA violation is proven, companies will be charged between $5,000-$10,000
per false claim plus treble damages.80 For large manufacturers providing interstate products, this
can easily result in millions of dollars in damages. The magnitude of FCA damages in relation to
large pharmaceutical manufacturers is best illustrated by examining the 2016 settlement
involving Wyeth and Pfizer Inc. (Pfizer purchased Wyeth for $68 billion in 2009).81 Wyeth and
Pfizer settled with the Department of Justice in 2016 for $784.6 million in regards to “Wyeth’s
knowing false and fraudulent prices on two of its’ proton pump inhibitor (PPI) drugs, Protonix
Oral and Protonix IV.”82 Principal Deputy Assistant Attorney General Benjamin C. Mizer
discussing the settlement stated “[t]his settlement demonstrates our unwavering commitment to
hold pharmaceutical companies responsible for pursuing pricing schemes that attempt to
manipulate and overcharge federal health care programs – programs that protect the poor and
disabled – for drugs sold to commercial customers at much lower prices.”83
Second, under the FCA, private individuals can bring qui tam actions against
corporations. These private individuals need specific knowledge about the violations.84 This
scienter requirement usually means the relators will be employees of the company. If any
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employee learns of the manufacturers knowing misclassification, either through word of mouth
or billing practices, this will allow a qui tam action to ensue.
Third, enrolling in the MDRP allows pharmaceutical manufacturers to guarantee their
products are better represented on the Medicaid ledgers, therefore, prescribed more often. This
provides a substantial financial benefit even though it contains a rebate subscription. If a
manufacturer is found in violation of the FCA, CMS has the ability to bar the company from
participating in any federal government program going forward.85 This can equate to a financial
death penalty for companies that rely heavily on federal reimbursement to stay afloat. These
three penalties for violating the FCA should serve as a substantial deterrent for pharmaceutical
manufacturers to properly classify their drug when enrolling in the MDRP.
VI.

Conclusion
Compliance with CMS’s Covered Outpatient final rule still allows for a gap in the

classifications that needs to be filled with a more precise placement of these products that have
the potential to create Medicaid fraud. This potential fraud should be thrust to the forefront when
taking into consideration the lasting ramifications it may have on taxpayers. Following the
enactment of the ACA’s Medicaid Expansion plan, the total amount of people currently
receiving health care benefits through Medicaid or CHIP (Children’s Health Insurance Program)
is approximately 70 million.86 This was following the Supreme Court’s ruling that state Medicaid
expansion must be voluntary.87 For a vast majority of this population, Medicaid is the only way
they can afford health care. Therefore, it is imperative that the taxpayer’s and federal
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government’s funds are treated with the utmost respect and fiscal responsibility. Creating this
new classification system for DDCPs will help conserve money for the citizens and held to
appropriately allocate money from the federal budget. At the time of this writing the new
President Donald Trump’s regime is attempting to implement a new federal health care policy to
replace the Patient Protection and Affordable Care Act. With the health care sector preparing for
a potential shift, this proposed legislation coupled with the deterrence of a False Claims Act
violation, has the potential to create a framework for CMS to follow in the coming years.
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